A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies

Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Melissa T., Yuan, Long, Klee, Alyssa N., Freeman, Gordon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451140/
https://www.ncbi.nlm.nih.gov/pubmed/35925787
http://dx.doi.org/10.1089/mab.2021.0068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451140/
https://www.ncbi.nlm.nih.gov/pubmed/35925787
http://dx.doi.org/10.1089/mab.2021.0068

Ejemplares similares